William Blair & Company
NVCR icon

William Blair & Company’s NovoCure NVCR Stock Holding History

William Blair & Company’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,406
Closed -$307K – 1827
2023
Q2 		$307K Buy
7,406
+906
+14% +$56.3K ﹤0.01% 1245
2023
Q1 		$391K Sell
6,500
-300
-4% -$24K ﹤0.01% 1133
2022
Q4 		$499K Hold
6,800
– – ﹤0.01% 1043
2022
Q3 		$517K Sell
6,800
-100
-1% -$7.8K ﹤0.01% 1028
2022
Q2 		$480K Sell
6,900
-3
-0% -$226 ﹤0.01% 1079
2022
Q1 		$572K Buy
+6,903
New +$508K ﹤0.01% 1110
2021
Q3 		– Sell
-1,775
Closed -$394K – 1921
2021
Q2 		$394K Hold
1,775
– – ﹤0.01% 1243
2021
Q1 		$235K Buy
1,775
+200
+13% +$31.6K ﹤0.01% 1421
2020
Q4 		$273K Buy
+1,575
New +$216K ﹤0.01% 1310

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

William Blair & Company's NVCR Position: Q3 2023 in Review

William Blair & Company sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 7,406 shares — an estimated $307K sold.

William Blair & Company first reported a position in NVCR in Q4 2020 and held it in 9 quarters. The position peaked at $572K in Q1 2022. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • William Blair & Company reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • William Blair & Company sold 7,406 NovoCure shares in Q3 2023, an estimated $307K.
  • William Blair & Company first reported a position in NovoCure in Q4 2020 and held it in 9 quarters.
  • William Blair & Company's NovoCure position peaked at $572K in Q1 2022.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on William Blair & Company's 13F filing for Q3 2023, filed 9 Nov 2023.